Evaluation of the Efficacy and Safety of XTR004 Injection in Detecting Blood Flow Restrictive Stenosis in Patients With Suspected or Known Stable Coronary Artery Disease: A Multicenter, Open-Label, Phase III Clinical Trial
Latest Information Update: 18 Mar 2026
At a glance
- Drugs XTR 004 (Primary)
- Indications Coronary artery disease
- Focus Registrational; Therapeutic Use
- Sponsors Sinotau Pharmaceuticals
Most Recent Events
- 04 Mar 2026 New trial record
- 03 Mar 2026 The protocol has been amended to change in interventional study model to single group assignment.